Global Innovation Index 2026 - Special theme 2026: Powering entrepreneurs at the frontier of science, turning pilots into pipelines

The Global Innovation Index 2026 special chapter on deep science entrepreneurship warns that while public and private R&D spending has reached historic highs—“inching closer to the USD 3 trillion mark”—the translation of frontier research into scalable industries remains constrained by intrinsic scientific and market barriers. The chapter, produced by contributors from Dealroom.co, EPFL, the University of Groningen and WIPO, leverages new datasets including the Dealroom–WIPO Deep Science Startup Tracker and the SPARK study on patenting to map which startups and spinouts are able to scale and which obstacles block their progress.

"The very traits which make a discovery valuable, namely, its novelty, complexity and distance from existing markets, are precisely what makes it difficult and costly to commercialize," the chapter states, framing the science-to-industry gap as an inherent feature of deep science entrepreneurship rather than a temporary policy failure.

Context and key findings

The chapter defines deep science entrepreneurship narrowly to exclude software, e-commerce and other digital-native services, focusing instead on fields such as advanced materials, energy science, genomics, health technologies, quantum physics and synthetic biology. Authors Lorenzo Chiavarini and Felix Ullmer (Dealroom.co), Gaétan de Rassenfosse (EPFL), Kritika Saxena (University of Groningen) and WIPO researchers Davide Bonaglia, Christopher Harrison, Hong Kan, Shengyu Qin and Sacha Wunsch-Vincent underline four distinguishing features of deep science ventures:

• Longer development cycles—validation, prototyping, regulatory approval, clinical testing and manufacturing scale-up can span five to 15 years before revenue.
• Higher capital intensity—wet labs, clean rooms, pilot plants and other specialized infrastructure are often required prior to product-market fit.
• Interdisciplinary, shifting teams—successful scaling requires the integration of research, regulatory, process engineering and commercialization capabilities.
• Clear intellectual property architecture—defensible IP underpins collaboration, licensing and investment decisions.

The chapter draws on prior research to frame the problem. It cites Bonaglia et al. (2025) on rising R&D spending and references literature by Bloom et al. (2020) and Park et al. (2023) suggesting that disruptive discovery may be becoming harder. It also notes empirical work on financing gaps—“valleys of death”—and the need for multi-stage validation cited from Auerswald and Branscomb (2003) and Vohora et al. (2004).

New empirical tools are central to the analysis: the Dealroom–WIPO Deep Science Startup Tracker offers the first global mapping of deep science startups, while SPARK: Patenting in Deep Science Startups and Spinouts provides an IP-focused complement to the mapping effort. Background studies by de Rassenfosse (2026) and Saxena (2026) supply a literature review and evidence on developing-economy dynamics respectively.

Outlook

The chapter concludes that closing the corridor from laboratory to market will require policy mixes and ecosystem interventions tailored to the unique timelines, capital needs and IP sensitivities of deep science ventures. With global R&D approaching the USD 3 trillion threshold and an unprecedented volume of frontier-science activity, the authors argue the imperative is not only to increase funding but to redesign financing, infrastructure and regulatory pathways so pilots can become repeatable pipelines for growth and productivity.